Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
QDEL Stock Forecast 2026-2027
$17.38
Current Price
$1.18B
Market Cap
Buy 1
Hold 2
Sell 1
Wall St Analyst Ratings
Distance to QDEL Price Targets
+118.6%
To High Target of $38.00
-7.9%
To Median Target of $16.00
-31.0%
To Low Target of $12.00
QDEL Price Momentum
-4.9%
1 Week Change
+27.1%
1 Month Change
-31.7%
1 Year Change
-39.1%
Year-to-Date Change
-51.2%
From 52W High of $35.58
+75.2%
From 52W Low of $9.92
📊 TOP ANALYST CALLS
Did QDEL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Quidel is one of their latest high-conviction picks.
Latest QDEL Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, QDEL has a neutral consensus with a median price target of $16.00 (ranging from $12.00 to $38.00). The overall analyst rating is Buy (6.5/10). Currently trading at $17.38, the median forecast implies a -7.9% downside. This outlook is supported by 1 Buy, 2 Hold, and 1 Sell ratings.
Conversely, the most conservative target is provided by Casey Woodring at JP Morgan, suggesting a 31.0% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
QDEL Analyst Ratings
1
Buy
2
Hold
1
Sell
QDEL Price Target Range
Low
$12.00
Average
$16.00
High
$38.00
Current: $17.38
Latest QDEL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for QDEL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 8, 2026 | Citigroup | Patrick Donnelly | Neutral | Maintains | $18.00 |
| Jul 1, 2026 | JP Morgan | Casey Woodring | Underweight | Maintains | $12.00 |
| May 7, 2026 | Jefferies | Hold | Downgrade | $N/A | |
| May 6, 2026 | Citigroup | Neutral | Maintains | $N/A | |
| Apr 10, 2026 | UBS | Neutral | Maintains | $N/A | |
| Feb 12, 2026 | Citigroup | Neutral | Maintains | $N/A | |
| Jan 21, 2026 | UBS | Neutral | Maintains | $N/A | |
| Nov 7, 2025 | JP Morgan | Underweight | Maintains | $N/A | |
| Nov 6, 2025 | UBS | Neutral | Maintains | $N/A | |
| Oct 7, 2025 | Citigroup | Neutral | Downgrade | $N/A | |
| Aug 7, 2025 | UBS | Neutral | Maintains | $N/A | |
| Aug 6, 2025 | Citigroup | Buy | Maintains | $N/A | |
| May 8, 2025 | UBS | Neutral | Maintains | $N/A | |
| May 8, 2025 | Jefferies | Buy | Upgrade | $N/A | |
| Apr 21, 2025 | JP Morgan | Underweight | Maintains | $N/A | |
| Feb 13, 2025 | RBC Capital | Outperform | Maintains | $N/A | |
| Feb 13, 2025 | UBS | Neutral | Maintains | $N/A | |
| Dec 11, 2024 | Citigroup | Buy | Upgrade | $N/A | |
| Dec 10, 2024 | Jefferies | Hold | Initiates | $N/A | |
| Sep 19, 2024 | UBS | John Sourbeer | Neutral | Upgrade | $50.00 |
QuidelOrtho Corporation (QDEL) Competitors
The following stocks are similar to Quidel based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
QuidelOrtho Corporation (QDEL) Financial Data
QuidelOrtho Corporation has a market capitalization of $1.18B with a P/E ratio of -1.0x. The company generates $2.66B in trailing twelve-month revenue with a -45.6% profit margin.
Revenue growth is -10.5% quarter-over-quarter, while maintaining an operating margin of -4.1% and return on equity of -49.9%.
Valuation Metrics
Market Cap
$1.18B
Enterprise Value
$3.98B
P/E Ratio
-1.0x
PEG Ratio
0.0x
Price/Sales
0.5x
Growth & Margins
Revenue Growth (YoY)
-10.5%
Gross Margin
+42.6%
Operating Margin
-4.1%
Net Margin
-45.6%
EPS Growth
-10.5%
Financial Health
Cash/Price Ratio
+11.8%
Current Ratio
1.4x
Debt/Equity
155.3x
ROE
-49.9%
ROA
+0.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
QuidelOrtho Corporation (QDEL) Business Model
About QuidelOrtho Corporation
What They Do
Manufactures diagnostic testing solutions for healthcare.
Business Model
QuidelOrtho Corporation generates revenue by developing and providing a diverse range of diagnostic products, including rapid tests and laboratory assays, aimed at detecting various medical conditions. Their offerings cater to clinical laboratories, hospitals, and primary care settings, enabling healthcare professionals to make informed decisions based on reliable and timely diagnoses.
Additional Information
The company has a significant impact on public health, particularly during health crises, and remains relevant amid increasing demand for accurate testing solutions globally. QuidelOrtho's focus on innovation positions it as a key player in the healthcare sector.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
6,500
CEO
Mr. Brian J. Blaser
Country
United States
IPO Year
1992
Website
www.quidelortho.comQuidelOrtho Corporation (QDEL) Latest News & Analysis
Latest News
Quick Summary
QuidelOrtho Corporation granted 356,555 restricted stock units to CFO Micah Young as part of its 2026 Inducement Plan, approved by the Board's Compensation Committee.
Why It Matters
The grant of RSUs to the CFO signals confidence in leadership and aligns executive interests with shareholder value, potentially influencing stock performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
QuidelOrtho Corporation's market cap has dropped $5B post-merger, with a 40% decline since February. Disappointing Q4/Q1 results and lowered 2026 EPS guidance to $1.85 raise investor concerns.
Why It Matters
QuidelOrtho's significant market cap loss and disappointing earnings guidance highlight financial instability, raising concerns about profitability and future growth, impacting investor confidence.
Source: Seeking Alpha
Market Sentiment:
Negative
Quick Summary
QuidelOrtho (QDEL) saw a rise in share price with increased trading volume, but recent earnings estimate revisions indicate potential weakness ahead.
Why It Matters
QuidelOrtho's share price surge amidst high trading volume indicates short-term interest, but stagnant earnings estimates may signal limited future growth potential.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
QuidelOrtho Corporation appointed Micah Young as Chief Financial Officer, effective July 6, 2026, succeeding Joseph M. Young brings over 20 years of experience in medical technology finance.
Why It Matters
The appointment of a seasoned CFO like Micah Young can signal strategic shifts, potential improvements in financial management, and impact investor confidence in QuidelOrtho's future performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
QDEL shows growth potential with a strong portfolio and cost-saving measures, but faces risks due to reliance on respiratory products amid mixed first-quarter results.
Why It Matters
QDEL's growth potential is underpinned by a strong portfolio and cost savings, but reliance on respiratory products poses a risk, affecting future earnings stability.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Investors should monitor QDEL stock due to recent activity in the options market.
Why It Matters
Increased activity in the options market for QDEL stock may indicate anticipated volatility or significant price movement, signaling potential investment opportunities or risks.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Frequently Asked Questions About QDEL Stock
What is QuidelOrtho Corporation's (QDEL) stock forecast for 2027?
Based on our analysis of 11 Wall Street analysts, QuidelOrtho Corporation (QDEL) has a median price target of $16.00. The highest price target is $38.00 and the lowest is $12.00.
Is QDEL stock a good investment in 2027?
According to current analyst ratings, QDEL has 1 Buy ratings, 2 Hold ratings, and 1 Sell ratings. The stock is currently trading at $17.38. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for QDEL stock?
Wall Street analysts predict QDEL stock could reach $16.00 in the next 12 months. This represents a -7.9% decrease from the current price of $17.38. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is QuidelOrtho Corporation's business model?
QuidelOrtho Corporation generates revenue by developing and providing a diverse range of diagnostic products, including rapid tests and laboratory assays, aimed at detecting various medical conditions. Their offerings cater to clinical laboratories, hospitals, and primary care settings, enabling healthcare professionals to make informed decisions based on reliable and timely diagnoses.
What is the highest forecasted price for QDEL QuidelOrtho Corporation?
The highest price target for QDEL is $38.00 from at , which represents a 118.6% increase from the current price of $17.38.
What is the lowest forecasted price for QDEL QuidelOrtho Corporation?
The lowest price target for QDEL is $12.00 from Casey Woodring at JP Morgan, which represents a -31.0% decrease from the current price of $17.38.
What is the overall QDEL consensus from analysts for QuidelOrtho Corporation?
The overall analyst consensus for QDEL is neutral. Out of 11 Wall Street analysts, 1 rate it as Buy, 2 as Hold, and 1 as Sell, with a median price target of $16.00.
How accurate are QDEL stock price projections?
Stock price projections, including those for QuidelOrtho Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 2:51 AM UTC